NeuroOne Medical Technologies (NASDAQ:NMTC) and CVRx (NASDAQ:CVRX) Head-To-Head Analysis

CVRx (NASDAQ:CVRX) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for CVRx and NeuroOne Medical Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	1	3	2	0	2.17
NeuroOne Medical Technologies	1	1	3	0	2.40

CVRx presently has a consensus target price of $4.30, indicating a potential upside of 172.15%. NeuroOne Medical Technologies has a consensus target price of $7.33, indicating a potential upside of 554.76%. Given NeuroOne Medical Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than CVRx.

Institutional & Insider Ownership

75.3% of CVRx shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 16.6% of CVRx shares are held by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

CVRx has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

Profitability

This table compares CVRx and NeuroOne Medical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CVRx	-84.93%	-152.35%	-50.93%
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%

Valuation and Earnings

This table compares CVRx and NeuroOne Medical Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$56.65 million	0.74	-$53.31 million	($1.98)	-0.80
NeuroOne Medical Technologies	$12.10 million	0.84	-$3.61 million	($0.95)	-1.18

NeuroOne Medical Technologies has lower revenue, but higher earnings than CVRx. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.

Summary

NeuroOne Medical Technologies beats CVRx on 8 of the 13 factors compared between the two stocks.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.